Position Title

Internal Medicine: HMCT - Lymphoma Hematology

Responsibilities:

• Provide inpatient and outpatient care for lymphoma patients.  Outpatient sub-specialization to specific lymphoma subtypes is possible, particularly if it aligns with research interests.
• Serve as local and national principal investigator on lymphoma clinical trials.  It is anticipated that the candidate will have interest in early phase drug development and actively participate in phase 1 clinical trials.
• Publish in national peer-reviewed journals and present in national scientific meetings. 
• Provide education and mentorship to hematology/oncology fellows, internal medicine residents and medical students.
• KU Cancer Center provides extremely competitive salary and benefits including a bonus structure for clinical productivity.

Organization:

• KU Cancer Center was recently recognized as an NCI-designated Comprehensive Cancer Center and has been a long-standing CIBMTR BMT CTN affiliate center.  We have been ranked for 12 consecutive years in US News & World Report's "Best Hospital" designation for Cancer Hospitals, achieved Magnet nursing designation in 2006, and consistently earn national recognition for outstanding quality and safety.
• The HMCT Division is comprised of 21 faculty experts dedicated to the care of patients with hematologic malignancies and immune deficiencies.  We are committed to developing basic science in hematologic malignancies, translating those discoveries into novel therapeutics, and participating in landmark clinical research leading to drug development and approval.  
• The HMCT division recently received a $66M philanthropic gift that was utilized to construct a state-of-the-art 84 bed inpatient care unit dedicated to patients with hematologic malignancies housed within our 1,045-bed academic medical center.
• HMCT therapeutics division operates a large, state-of-the-art, outpatient care facility, therapeutic blood treatment/apheresis center, and inpatient center.
• The division includes a robust, FACT accredited, Immune Effector Cell (IEC) program that performs autologous and allogenic transplants, CAR T-cell and cellular therapeutics for blood cancers, congenital hematologic disorders, and solid tumors.  We were a top 3 enrolling site for ZUMA-7 and BELINDA and perform more than 300 transplants and CAR-T procedures annually.
• The HMCT division has a comprehensive portfolio of pharma-sponsored and investigator-initiated BMT and CAR-T and cell therapy clinical trials and is also a certified CAR-T center for Novartis, Kite and BMS.  KU Cancer Center enjoys a fully taxpayer funded early phase clinical trial center dedicated to development of novel therapeutics. 
• KU Cancer Center is a member site of SWOG and ECOG, actively participating the in the Lymphoma committees of both.  We additionally are a member site of the lymphoma committee of the Hoosier Cancer Research Network specializing in early phase cooperative group studies

Kansas City:

• Bi-state population of greater than 2 million that serves as the regional metropolitan hub for a larger catchment within an approximately 200-mile radius
• A "hidden gem" winning the award of America's 4th most Cultured City by Travel+Leisure magazine
• Affordable housing including downtown lofts, suburban neighborhoods, and rural properties
• New international airport is set to open in early 2023.
• A robust arts scene including symphony, ballet, theatre, and museums
• Sports enthusiasts can enjoy a variety of professional and collegiate sports
• Outdoor activities abound with more than 600 parks and 24 public lakes

For more information contact:

Alison Woods

awoods9@kumc.edu

We are an equal employment opportunity employer without regard to a person’s race, color, religion, sex (including pregnancy, gender identity and sexual orientation), national origin, ancestry, age (40 or older), disability, veteran status or genetic information.